Signaling to gene activation and cell death by tumor necrosis factor receptors and Fas

International Review of Cytology

Volumn 214, Issue , 2002, Pages 225-272

  Beyaert, Rudi ^a   Van Loo, Geert ^a   Heyninck, Karen ^a   Vandenabeele, Peter ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Apoptosis; Caspases; Death receptors; Fas; Inflammation; MAP kinases; Necrosis; NF B; TNF

Indexed keywords

CASPASE; CD30 ANTIGEN; CD40 ANTIGEN; FAS ANTIGEN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 3; NITRIC OXIDE SYNTHASE; PROTEIN P55; PROTEIN P75; RANTES; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TYPE; CYTOTOXICITY; GENE ACTIVATION; HUMAN; INFLAMMATION; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0036186666     PISSN: 00747696     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7696(02)14007-1     Document Type: Article

References (343)

1. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis
2. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of 1pr mice
3. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver
4. FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase
5. The Bcl-2 protein family: Arbiters of cell survival
6. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors
7. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus
8. Tumor necrosis factors: Developments during the last decade
9. Human tumor necrosis factor. Production, purification, and characterization
10. CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP
11. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling
12. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
13. Extracellular matrix interacts with soluble CD95L: Retention and enhancement of cytotoxicity
14. Tumor necrosis factor receptor-associated factors (TRAFs) - A family of adapter proteins that regulates life and death
15. Death receptors: Signaling and modulation
16. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation
17. Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants
18. Signaling by proinflammatory cytokines: Oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain
19. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice
20. Embryonic lethality and liver degeneration in mice lacking the ReIA component of NF-kappa B
21. A role for CD95 ligand in preventing graft rejection
22. Defects in regulation of apoptosis in caspase-2-deficient mice
23. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells
24. Casein kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis
25. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor
26. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappaB-dependent gene expression and apoptosis
27. Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity
28. ADAMs: Focus on the protease domain
29. Metalloprotease-disintegrins: Links to cell adhesion and cleavage of TNF alpha and Notch
30. A protein related to a proteasomal subunit binds to the intracellular domain of the p55 TNF receptor upstream to its "death domain"
31. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain
32. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death
33. Structure/function analysis of p55 tumor necrosis factor receptor and fas-associated death domain. Effect on necrosis in L929sA cells
34. Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes
35. Prolonged activation of jun and collagenase genes by tumor necrosis factor-alpha
36. MADD is highly homologous to a Rab3 guanine-nucleotide exchange protein (Rab3-GEP)
37. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia
38. Caspase activation involves the formation of the aposome, a large (approximately 700 kDa) caspase-activating complex
39. Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes
40. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin
41. An endotoxin-induced serum factor that causes necrosis of tumors
42. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing
43. Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development
44. A crucial role for p80 TNF-R2 in amplifying p60 TNF-R1 apoptosis signals in T lymphocytes
45. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling
46. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx
47. Apoptotic features of selective neuronal death in ischemia, epilepsy and gp 120 toxicity
48. Interdigital cell death can occur through a necrotic and caspase-independent pathway
49. Regulation of DNA binding by Re1/NF-kappaB transcription factors: Structural views
50. Functional redundancy of the nuclear factor kappa B inhibitors I kappa B alpha and I kappa B beta
51. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis
52. Direct cleavage by the calcium-activated protease calpain can lead to inactivation of caspases
53. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases
54. Phosphorylation of tumor necrosis factor receptor CD120a (p55) by p42(mapk/erk2) induces changes in its subcellular localization
55. Identification of a protein kinase associated with the cytoplasmic domain of the p60 tumor necrosis factor receptor
56. The p60 tumor necrosis factor (TNF) receptor-associated kinase (TRAK) binds residues 344-397 within the cytoplasmic domain involved in TNF signaling
57. Cooperation of both TNF receptors in inducing apoptosis: Involvement of the TNF receptor-associated factor binding domain of the TNF receptor 75
58. Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor
59. Cathepsin D protease mediates programmed cell death induced by interferon-gamma. Fas/APO-1 and TNF-alpha
60. Phosphatidyl serine exposure during apoptosis precedes release of cytochrome c and decrease in mitochondrial transmembrane potential
61. Apoptotic and necrotic cell death induced by death domain receptors
62. Death receptor-induced apoptotic and necrotic cell death: Differential role of caspases and mitochondria
63. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain
64. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation
65. The zinc finger protein A20 interacts with a novel anti-apoptotic protein which is cleaved by specific caspases
66. X-linked IAP is a direct inhibitor of cell-death proteases
67. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
68. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation
69. The 55-kDa tumor necrosis factor receptor induces clustering of mitochondria through its membrane-proximal region
70. The inhibitor of death receptor signaling. FLICE-inhibitory protein defines a new class of tumor progression factors
71. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R
72. Role of the 75-kDa TNF receptor in TNF-induced activation of neutrophil respiratory burst
73. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
74. RAIDD is a new "death" adaptor molecule
75. CD30-dependent degradation of TRAF2: Implications for negative regulation of TRAF signaling and the control of cell survival
76. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors
77. Two-hybrid cloning of a gene encoding TNF receptor-associated protein 2, a protein that interacts with the intracellular domain of the type 1 TNF receptor: Identity with subunit 2 of the 26S protease
78. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis
79. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages
80. Involvement of an ICE-like protease in Fas-mediated apoptosis
81. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD
82. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity
83. Decreased sensitivity to tumornecrosis factor but normal T-cell development in TNF receptor-2-deficient mice
84. Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor
85. Apoptosis: Getting rid of the bodies
86. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF
87. Anti-TNFα therapy of rheumatoid arthritis: What have we learned?
88. In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains
89. More than one way to die: Apoptosis, necrosis and reactive oxygen damage
90. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
91. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent
92. Recombinant tumor necrosis factor: Its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines
93. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells
94. TNFRSF1A mutations and autoinflammatory syndromes
95. Antinflammatory effects of CD95 ligand (FasL)-induced apoptosis
96. CASH, a novel caspase homologue with death effector domains
97. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity
98. Redox regulation of TNF signaling
99. TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis
100. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor
101. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: A role for TNF-R1 activation by endogenous membrane-anchored TNF
102. Fas ligand-induced apoptosis as a mechanism of immune privilege
103. Cell membrane permeabilization and cellular collapse, followed by loss of dehydrogenase activity: Early events in tumour necrosis factor-induced cytotoxicity
104. BCL-2 family members and the mitochondria in apoptosis
105. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death
106. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
107. Differential requirement for caspase 9 in apoptotic pathways in vivo
108. MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death
109. Characterization of xiap-deficient mice
110. The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN
111. Identification of Grb2 as a novel binding partner of tumor necrosis factor (TNF) receptor 1
112. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis
113. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule
114. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation
115. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways
116. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex
117. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis
118. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase
119. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain
120. The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis
121. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis
122. Inhibition of death receptor signals by cellular FLIP
123. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen
124. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
125. Major heat shock protein hsp70 protects tumor cells from tumor necrosis factor cytotoxicity
126. Role of the 75-kDa tumor necrosis factor receptor: Inhibition of early hematopoiesis
127. Caspasecleaved TRAF1 negatively regulates the antiapoptotic signals of TRAF2 during TNF-induced cell death
128. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains
129. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death
130. How NF-kappaB is activated: The role of the IkappaB kinase (IKK) complex
131. Phosphorylation meets ubiquitination: The control of NF-κB activity
132. Living, a novel inhibitor-of-apoptosis (IAP) family member
133. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways
134. Caspase-independent cell killing by Fas-associated protein with death domain
135. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal
136. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
137. Resistance to the cytotoxic effects of tumor necrosis factor alpha can be overcome by inhibition of a FADD/caspase-dependent signaling pathway
138. Activation of death-inducing signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP
139. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor
140. Caspase-independent programmed cell death with necrotic morphology
141. Cytokine-binding proteins: Stimulating antagonists
142. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice
143. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation
144. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease
145. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies
146. Apoptosis. Searching for FLASH domains
147. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia
148. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF
149. Mitochondrial control of cell death
150. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme
151. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice
152. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9
153. Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family
154. Activation of IkappaB kinase beta by protein kinase C isoforms
155. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice
156. TRAF-interacting protein (TRIP): A novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation
157. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival
158. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release
159. The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure
160. Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis
161. Clinical applications of TNF-alpha in cancer
162. TRAF1 is a substrate of caspases activated during tumor necrosis factor receptor-a induced apoptosis
163. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation
164. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific
165. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
166. Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced apoptosis
167. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock
168. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
169. Severe liver degeneration in mice lacking the 1kappaB kinase 2 gene
170. IKK1-deficient mice exhibit abnormal development of skin and skeleton
171. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis
172. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis
173. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues
174. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes
175. Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin
176. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation, during apoptosis
177. The TNF and TNF receptor superfamilies: Integrating mammalian biology
178. Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells
179. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis
180. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
181. Cardiolipin provides specificity for targeting of tBid to mitochondria
182. Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti
183. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1
184. Activation of a proapoptotic amplification loop through inhibition of NF-kappaB-dependent survival signals by caspase-mediated inactivation of RIP
185. Necrotic death pathway in Fas receptor signaling
186. RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase
187. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
188. Loss of Daxx, a promiscuously interacting protein, results in extensive apoptosis in early mouse development
189. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs
190. A reversible component of mitochondrial respiratory dysfunction in apoptosis can be rescued by exogenous cytochrome c
191. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
192. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens
193. Apoptosis by death factor
194. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: A lesson from the mouse model
195. Fas ligand-induced apoptosis
196. Fas ligand
197. The Fas death factor
198. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis
199. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta
200. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1
201. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes
202. FADD/MORT1 regulates the pre-TCR checkpoint and can function as a tumor suppressor
203. Effects of a dominant interfering mutant of FADD on signal transduction in activated T cells
204. Caspases: Killer proteases
205. Apoptosis and necrosis: Different execution of the same death
206. ASK1 is essential for JNK/SAPK activation by TRAF2
207. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor
208. Immune privilege or inflammation? Insights into the Fas ligand enigma
209. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen
210. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity
211. Mass spectrometric identification of proteins released from mitochondria undergoing permeability transition
212. Caspase inhibition reveals functional cooperation between p55- and p75-TNF receptors in cell necrosis
213. Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin
214. Biochemical properties of the 75-kDa tumor necrosis factor receptor. Characterization of ligand binding, internalization, and receptor phosphorylation
215. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact
216. An essential role for ectodomain shedding in mammalian development
217. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. Monocytogenes infection
218. Regulated commitment of TNF receptor signaling: A molecular switch for death or activation
219. Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells
220. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
221. The CD95 (APO-1/Fas) receptor activates NF-kappaB independently of its cytotoxic function
222. Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils
223. Shedding of tumor necrosis factor receptors by activated human neutrophils
224. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor, Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils
225. Activation of the Ikappa B kinases by RIP via IKKgamma/NEMO-mediated oligomerization
226. Cell death attenuation by "Usurpin," a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex
227. Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1)
228. Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production
229. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: A new role for Fas ligand in inflammatory responses
230. Cooperative signaling by tumor necrosis factor receptors CD120a (p55) and CD120b (p75) in the expression of nitric oxide and inducible nitric oxide synthase by mouse macrophages
231. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
232. Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes
233. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor
234. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40
235. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins
236. 1-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction
237. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex
238. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity
239. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy
240. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases
241. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice
242. Rabbit tumor necrosis factor: Mechanism of action
243. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis
244. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain
245. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation
246. Corpse clearance defines the meaning of cell death
247. Two CD95 (APO-I/Fas) signaling pathways
248. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells
249. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells
250. MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase
251. NEMO/IKK gamma-deficient mice model incontinentia pigmenti
252. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction
253. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity
254. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation
255. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF
256. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses
257. Casper is a FADD- and caspase-related inducer of apoptosis
258. Tumor necrosis factor activities and cancer therapy-A perspective
259. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner
260. Identification of a protein with homology to hsp90 that binds the type l tumor necrosis factor receptor
261. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation
262. Simplification of complex peptide mixtures for proteomic analysis: Reversible biotinylation of cysteinyl peptides
263. TNF receptor p55 controls early acute graft-versus-host disease
264. Signal-induced ubiquitination of 1kappaBalpha by the F-box protein Slimb/beta-TrCP
265. Molecular ordering of the Fas-apoptotic pathway: The Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases
266. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis
267. Lysosomal protease pathways to apoptosis: Cleavage of bid, not procaspases, is the most likely route
268. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-A mechanism of immune evasion?
269. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
270. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing
271. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis
272. Mitochondrial release of caspase-2 and -9 during the apoptotic process
273. Molecular characterization of mitochondrial apoptosis-inducing factor
274. Two distinct pathways leading to nuclear apoptosis
275. SADS: A new component of Fas-DISC is the accelerator for cell death signaling and is downregulated in patients with colon carcinoma
276. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand
277. An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators
278. 1kappa B family members function by different mechanisms
279. Expression of the functional soluble form of human fas ligand in activated lymphocytes
280. Fas ligand in human serum
281. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes
282. Embryonic leathality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice
283. The two different receptors for tumor necrosis factor mediate distinct cellular responses
284. Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor
285. A novel domain within the 55 kd TNF receptor signals cell death
286. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product
287. Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses
288. Identification of CARDIAK, a RIP-like kinase that associates with caspase-1
289. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis
290. Monoclonal antibody-mediated tumor regression by induction of apoptosis
291. Inhibition of fas death signals by FLIPs
292. cDNA cloning and functional analysis of the p97 subunit of the 26S proteasome, a polypeptide identical to the type-1 tumor-necrosis-factor-receptor-associated protein-2/55.11
293. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors
294. Identification of paracaspases and metacaspases: Two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma
295. Life and death decisions: Regulation of apoptosis by proteolysis of signaling molecules
296. Characterization of seven murine caspase family members
297. Identification of a new caspase homologue: Caspase-14
298. Molecular cloning and identification of murine caspase-8
299. The proteolytic procaspase activation network: An in vitro analysis
300. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma
301. Two tumour necrosis factor receptors: Structure and function
302. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor
303. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore
304. Phosphorylation of the membrane proximal region of tumor necrosis factor receptor CD120a (p55) at ERK consensus sites
305. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally
306. Tumor necrosis factor-induced necrosis versus anti-Fas-induced apoptosis in L929 cells
307. Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic cell death pathways
308. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor
309. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
310. Fas ligand-induced c-Jun kinase activation in lymphoid cells requires extensive receptor aggregation but is independent of DAXX, and Fas-mediated cell death does not involve DAXX, RIP, or RAIDD
311. Fas-associated death domain protein interleukin-1 beta-converting enzyme 2 (FLICE2), and ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling
312. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
313. Depressed Langerhans cell migration and reduced contact hypersensitivity response in mice lacking TNF receptor p75
314. Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE
315. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
316. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen
317. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c
318. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death
319. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling
320. Calpain functions in a caspase independent manner to promote apoptosis-like events during platelet activation
321. Induction of manganous superoxide dismutase by tumor necrosis factor: Possible protective mechanism
322. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes
323. Correction of accelerated autoimmune disease by early replacement of the mutated 1pr gene with the normal Fas apoptosis gene in the T cells of transgenic MRL-1pr/1pr mice
324. Cell death: The significance of apoptosis
325. Daxx, a novel Fas-binding protein that activates JNK and apoptosis
326. Identification of the receptor component of the 1kappaBalpha-ubiquitin ligase
327. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice
328. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis
329. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development
330. Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice
331. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
332. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor
333. Apaf1 is required for mitochondrial pathways of apoptosis and brain development
334. Identification of RIP3, a RIP-like kinase that activates apoptosis and NFkappaB
335. Tumor necrosis factor signaling to stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38. Germinal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase 1 and SAPK while receptor interacting protein associates with a mitogen-activated protein kinase kinase kinase upstream of MKK6 and p38
336. MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation
337. Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis
338. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1
339. Resistance to DNA fragmentation and chromatin condensation in mice lacking the DNA fragmentation factor 45
340. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation
341. Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: Role in the induction of interleukin 6
342. Divinations and surprises: Genetic analysis of caspase function in mice
343. Target protease specificity of the viral serpin CrmA. Analysis of five caspases